Assessing and reporting the adverse effects of antipsychotic medication: A systematic review of clinical studies, and prospective, retrospective, and cross-sectional research

Clinical Neuropharmacology

Volumn 39, Issue 1, 2016, Pages 29-39

  Longden, Eleanor ^a   Read, John ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF EAST LONDON   (United Kingdom)

Author keywords

Adverse effects; Antipsychotic drugs; Patient centered research; Subjective effects of drugs

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ABNORMAL DREAMING; ACNE; ADVERSE DRUG REACTION; AKATHISIA; AKINESIA; AMENORRHEA; ANHEDONIA; ANORGASMIA; ANXIETY; BLURRED VISION; BRADYKINESIA; CLINICAL STUDY; CONSTIPATION; CROSS-SECTIONAL STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG USE; DRY SKIN; DYSKINESIA; DYSPHORIA; DYSTONIA; EMOTIONAL DISORDER; EPISTAXIS; ERECTILE DYSFUNCTION; EXCESSIVE DREAMING; FEMALE; GALACTORRHEA; GYNECOMASTIA; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; MEMORY DISORDER; MENTAL DISEASE; MENTAL STRESS; MICTURITION DISORDER; MOOD DISORDER; MOUSE; NAUSEA; NONHUMAN; PARESTHESIA; PERSONAL EXPERIENCE; PHOTOSENSITIVITY; POLYDIPSIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RETROSPECTIVE STUDY; REVIEW; SEDATION; SIDE EFFECT; SKIN PRURITUS; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT RESPONSE; TREMOR; WEIGHT GAIN; WELLBEING; XEROSTOMIA; FACTUAL DATABASE; MENTAL DISORDERS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; HUMANS; MENTAL DISORDERS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84957844131     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000117     Document Type: Review

References (82)

1. Day JC, Wood G, Dewey M, et al. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry 1995;166(5):650-653.
2. Lader M. Some adverse effects of antipsychotics: prevention and treatment. J Clin Psychiatry 1998;60:18-21.
3. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100.
4. Awad AG, Voruganti LN, Heslegrave RJ, et al. Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol 1996;11:55-59.
5. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177-183.
6. Finn SE, Bailey JM, Schultz RT, et al. Subjective utility ratings of neuroleptics in treating schizophrenia. Psychol Med 1990;20:843-848.
7. Rogers A, Day JC, Williams B, et al. The meaning and management of neuroleptic medication: a study of patients with a diagnosis of schizophrenia. Soc Sci Med 1998;47:1313-1323.
8. Karow A, Czekalla J, Dittmann RW, et al. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry 2007;68:75-80.
9. Adrianzén C, Arango-Dávila C, Araujo DM, et al. Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: post hoc analysis from a 3-year observational study. Hum Psychopharmacol 2010;25:439-447.
10. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004;65:4-18.
11. Cem Atbasoglu E, Schultz SK, Andreasen NC. The relationship of akathisia with suicidality and depersonalization among patients with schizophrenia. J Neuropsychiatry Clin Neurosci 2001;13:336-341.
12. Breggin P. $1.5 Million Award in Child Tardive Dyskinesia Malpractice Available at: http://www.breggin.com/index.php?option=com- content&task=view&id=308. Accessed Feb 21, 2015.
13. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995;10:133-138.
14. Wolters HA, Knegtering R, Wiersma D, et al. Evaluation of the Subjects' Response to Antipsychotics Questionnaire. Int Clin Psychopharmacol 2006;21:63-69.
15. Yusufi BZ, Mukherjee S, Aitchison K, et al. Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale (ANNSERS). Schizophr Bull 2005;31:574.
16. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-962.
17. National Institute for Health and Clinical Excellence (NICE). Psychosis and Schizophrenia in Adults: Treatment and Management. NICE Clinical Guideline 178 NICE; 2014.
18. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001;285:437-443.
19. Pitrou I, Boutron I, Ahmad N, et al. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009;169(19): 1756-1761.
20. Singh S, Loke YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials 2012;13:138.
21. Papanikolaou PN, Churchill R, Wahlbeck K, et al. Safety reporting in randomized trials of mental health interventions. Am J Psychiatry 2004; 161(9):1692-1697.
22. Pope A, Adams C, Paton C, et al. Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used. Br J Psychiatry 2010;197(1):67-72.
23. Haddad PM, Das A, Keyhani S, et al. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. J Psychopharmacol 2012;26:15-26.
24. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003;182:199-204.
25. Gentile S. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review. Pharmacotherapy 2013;33:1087-1106.
26. Biswasl PN, Wilton LV, Pearcel GL, et al. The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharm 2001;15:265-271.
27. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097.
28. Feldman RS, Quenzer LF. Fundamentals of Neuropsychopharmacology Sinauer Associates; 1984.
29. Plaa GL, Willmore LJ. General principles. Toxicology. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs 4th ed. New York: Raven Press; 1995:51-60.
30. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29:321-326.
31. Schott G, Pachl H, Limbach U, et al. The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. Dtsch Arztebl Int 2010; 107:279-285.
32. Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials 2008;29: 109-113.
33. Hughes S, Cohen D, Jaggi R. Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study. BMJ Open 2014;4(7):e005535. doi:10.1136/bmjopen-2014-005535.
34. Lundh A, Sismondo S, Lexchin J, et al. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012.
35. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33(1):159-174.
36. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19.
37. Guy WA. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health Education and Welfare; 1976:534-537.
38. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.
39. Chouinard G, Ross-Chouinard A, Annable L, et al. Extrapyramidal Symptom Rating Scale. Can J Neurol 1980;7:233-239.
40. Guy WA. ECDEU Assessment Manual. Rockville, MD: National Institute of Mental Health, 1976.
41. Bobon D, Woggon B. The AMDP-system in clinical psychopharmacology. Br J Psychiatry 1986;148:467-468.
42. Inada T. Evaluation and Diagnosis of Drug-Induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to its Usage. Tokyo: Seiwa Shoten Publishers; 1996.
43. Gerlach J, Korsgaard S, Clemmesen P, et al. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand 1993;87:244-252.
44. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001;50(1-2):79-88.
45. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 2000;42(3):241-247.
46. Weiden P, Rapkin B, Mott T, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull 1994;20(2):297-310.
47. Matza LS, Phillips GA, Revicki DA, et al. Development of a clinician questionnaire and patient interview to assess reasons for antipsychotic discontinuation. Psychiatry Res 2011;189(3):463-468.
48. Rofail D, Gray R, Gournay K. The development and internal consistency of the Satisfaction with Antipsychotic Medication Scale. Psychol Med 2005; 35(7):1063-1072.
49. Schöttle D, Kammerahl D, Huber J, et al. Sexual problems in patients with schizophrenia. Psychiatr Prax 2009;36(4):160-168.
50. Ozbilen M, Adams CE. Systematic overview of Cochrane Reviews for anticholinergic effects of antipsychotic drugs. J Clin Psychopharmacol 2009;29(2):141-146.
51. Seeman MV. Antipsychotics and physical attractiveness. Clin Schizophr Relat Psychoses 2011;5(3):142-146.
52. Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: a content analysis of Internet data. Acta Psychiatr Scand 2009;120(2):102-111.
53. Novak L, Svab V. Antipsychotics side effects' influence on stigma of mental illness: focus group study results. Psychiatr Danub 2009;21(1):99-102.
54. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998;317(7167):1181-1184.
55. Yusufi B, Mukherjee S, Flanagan R, et al. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol 2007;22(4):238-243.
56. Corso DM, Pucino F, DeLeo JM, et al. Development of a questionnaire for detecting potential adverse drug reactions. Ann Pharmacother 1992; 26(7-8):890-896.
57. Weiden PJ, Miller AL. Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. J Psychiatr Pract 2001;7(1):41-47.
58. Rabkin JG, Markowitz JS, Ocepek-Welikson K, et al. General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. J Clin Psychopharmacol 1992;12(1): 3-10.
59. Barbui C, Nosè M, Bindman J, et al. Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol 2005;25: 521-526.
60. Byrne S, Walter G, Hunt G, et al. Self-reported side effects in children and adolescents taking risperidone. Australas Psychiatry 2010;18(1):42-45.
61. Chiang Yl, Klainin-Yobas P, Ignacio J, et al. The impact of antipsychotic side effects on attitudes towards medication in people with schizophrenia and related disorders. J Clin Nursing 2011;20(15-16):2172-2182.
62. Morrison P, Gaskill D, Meehan T, et al. The use of the Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) in clinical practice. Aust N Z J Ment Health Nurs 2000;9(4):166-176.
63. Segal SP, Cohen D, Marder SR. Neuroleptic medication and prescription practices with sheltered-care residents: a 12-year perspective. Am J Public Health 1992;82(6):846-852.
64. Hamer S, Haddad PM. Adverse effects of antipsychotics as outcome measures. Br J Psychiatry Suppl 2007;50:s64-s70.
65. Jensen PS, Buitelaar J, Pandina GJ, et al. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. Eur Child Adolesc Psychiatry 2007;16:104-120.
66. Leucht S, Heres S, Hamann J, et al. Methodological issues in current antipsychotic drug trials. Schizophr Bull 2008;34(2):275-285.
67. United States Food and Drug Administration (FDA). Coding Symbols for Thesaurus of Adverse Reaction Terms. Rockville, MD: FDA; 1990.
68. International Conference on Harmonisation (ICH). Medical Dictionary for Regulatory Activities, Version 2.1 Maintenance and Support Services Organization (MSSO); 1999.
69. Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005;19:16-27.
70. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162(3):441-449.
71. Angermeyer MC, Löffler W, Müller P, et al. Patients' and relatives' assessment of clozapine treatment. Psychol Med 2001;31(3):509-517.
72. Frank AF, Gunderson JG. The role of the therapeutic alliance in the treatment of schizophrenia. Relationship to course and outcome. Arch Gen Psychiatry 1990;47(3):228-236.
73. Chue P. The relationship between patient satisfaction and treatment outcomes in schizophrenia. J Psychopharmacol 2006;20:38-56.
74. Thornicroft G, Tansella M, Becker T, et al. The personal impact of schizophrenia in Europe. Schizophr Res 2004;69(2-3):125-132.
75. Fakhoury WK, Wright D, Wallace M. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int Clin Psychopharmacol 2001;16(3): 153-162.
76. Lambert M, Schimmelmann BG, Karow A, et al. Subjective well-being and initial dysphoric reaction under antipsychotic drugs-concepts, measurement and clinical relevance. Pharmacopsychiatry 2003;36: S181-S190.
77. Naber D, Riedel M, Klimke A, et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand 2005;111(2): 106-115.
78. Levine J. Ascertainment of side effects in psychopharmacologic clinical trials. In: Benkert O, Maier W, Rickels K. ed. Evaluation of Psychotropic Drugs, Psychopharmacology Series Springer-Verlag; 1990;8:130-135.
79. Dossenbach M, Hodge A, Anders M, et al. Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation. Int J Neuropsychopharmacol 2005;8(2): 195-201.
80. Hayashi K, Walker AM. Japanese and American reports of randomized trials: differences in the reporting of adverse effects. Control Clin Trials 1996;17(2):99-110.
81. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006;29(5):385-396.
82. Derry S, Loke YK, Aronson JK. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol 2001;1:7.